Skip to content

miRNA in Fetal Overgrowth

Placental miRNA (microRNA) Profile in Fetal Overgrowth Related to Maternal Obesity Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01935076
Acronym
MIFO
Enrollment
82
Registered
2013-09-04
Start date
2013-01-31
Completion date
2014-02-28
Last updated
2014-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Maternal obesity, Macrosomic, miRNA, Fetal overgrowth

Brief summary

The purpose of this study is to determine whether placental and umbilical cord blood miRNA expression is altered in women with obesity with macrosomic neonates to when compared to miRNA expression from control patients.

Detailed description

MicroRNA's are a class of non-coding RNA's that function as translational repressors and are thought to modulate tissue development, proliferation, differentiation and function. Differential expression of certain placental miRNA's has been associated with preeclampsia. The fetal origins of adult disease hypothesis suggests that risk factors from intrauterine environmental exposures affect the fetus' development during sensitive periods, and increases the risk of specific diseases in adult life. Our aim is to understand factors that predispose fetuses to fetal overgrowth in utero, especially in women with obesity. The objective of the study is to identify miRNA which are differentially expressed in the placenta and cord blood of pregnancies that are affected by fetal macrosomia to determine factors that may predispose fetuses to fetal overgrowth.

Interventions

BEHAVIORALNeonatal exposure to maternal obesity

Sponsors

University of Pennsylvania
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* singleton pregnancy * prenatal care & delivery at the Hospital of the University of Pennsylvania system * Normal glucose tolerance test results (less than 120 mg/dl)

Exclusion criteria

* Multiple gestation * under 18 years old, or over 45 years old * chronic hypertension * preeclampsia * chronic steroid use * diabetes * major fetal anomaly * connective tissue disorder requiring medication * active HIV * Hepatitis C

Design outcomes

Primary

MeasureTime frameDescription
Fetal OvergrowthDelivery date to up to 6 weeks post partumPlacental and cord blood samples will be studied for miRNA expression. The objective of the study is to identify miRNA which are differentially expressed in the placenta and cord blood of pregnancies that are affected by fetal macrosomia to determine factors that may predispose fetuses to fetal overgrowth.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026